Modular-Neck hip stems
and certain lot-specific sizes and offsets of LFIT Anatomic CoCr
V40 Femoral Heads. Additionally, we are responsible for certain
product liability claims, primarily related to certain hip products
sold by Wright Medical Group N.V. (Wright) prior to its 2014
divestiture of the OrthoRecon business.
We have incurred, and expect to incur in the future, costs
associated with the defense and settlement of claims and
lawsuits. Based on the information that has been received related
to the matters discussed above, our accrual for these matters
was
$
169
at
March 31, 2025
, representing our best estimate of
probable loss. The final outcomes of these matters are
dependent on many factors that are difficult to predict.
Accordingly the ultimate cost related to these matters may be
materially different than the amount of our current estimate and
accruals and could have a material adverse effect on our results
of operations and cash flows.
Other Contractual Obligations and Commitments
Our outstanding balances of confirmed invoices in the supplier
financing program were
$
66
and
$
71
at
March 31, 2025
and
December 31, 2024
and are included within
accounts payable
in
our Consolidated Balance Sheets.
NOTE 7 -
ACQUISITIONS
We acquire stock in companies and various assets that continue
to support our capital deployment and product development
strategies. In the
three months
2025
and
2024
cash paid for
acquisitions, net of cash acquired was
$
4,749
and
$
246
.
In February
2025
we completed the acquisition of Inari for
$
80
per share, or an aggregate purchase price of
$
4,745
, net of cash
acquired. Inari's product portfolio includes minimally invasive
products for the treatment of venous thromboembolism. Inari is
part of our Vascular business within MedSurg and
Neurotechnology. The purchase price allocation for Inari is based
on preliminary valuations, primarily related to developed
technology and customer relationships. Goodwill attributable to
the acquisition reflects the strategic benefits of expanding our
market presence, diversifying our product portfolio and advancing
innovations. This goodwill is not deductible for tax purposes
.
Share-based awards for Inari employees vested upon our
acquisition and a charge of
$
139
was recorded in selling, general
and administrative expenses in the
three months
2025
.
In 2024
we completed various acquisitions for total consideration
that includes
$
1,628
in upfront payments, net of cash acquired,
and
$
400
contingent upon the achievement of certain commercial
or clinical milestones. The combined acquisition-date fair values
of the contingent milestone payments totaled
$
208
. Goodwill of
$
304
and
$
858
was recorded within our Orthopaedics and our
MedSurg and Neurotechnology segments respectively. The
acquired companies expand the product portfolios of our
Instruments, Endoscopy, Medical and Neuro Cranial businesses
within MedSurg and Neurotechnology and our Trauma and
Extremities and Joint